Literature DB >> 14656067

Neuropathology of cognitively normal elderly.

D S Knopman1, J E Parisi, A Salviati, M Floriach-Robert, B F Boeve, R J Ivnik, G E Smith, D W Dickson, K A Johnson, L E Petersen, W C McDonald, H Braak, R C Petersen.   

Abstract

Despite general agreement about the boundaries of Alzheimer disease (AD), establishing a maximum limit for Alzheimer-type pathology in cognitively intact individuals might aid in defining more precisely the point at which Alzheimer pathology becomes clinically relevant. In this study, we examined the neuropathological changes in the brains of 39 longitudinally followed. cognitively normal elderly individuals (24 women, 15 men; age range 74-95, median 85 years). Neuropathological changes of the Alzheimer type were quantified by determining neurofibrillary tangle (NFT) staging by the method of Braak and Braak and by quantification of the abundance of diffuse, cored, and neuritic plaque burden using the scheme developed by the Consortium to Establish a Registry for Alzheimer Disease (CERAD). Vascular, Lewy body, and argyrophilic grain pathology were also assessed. We found 34 subjects (87%) with a Braak stage <IV; 32 subjects (82%) with less than moderate numbers of cored plaques and 37 subjects (95%) with less than moderate numbers of tau-positive neuritic plaques. Many subjects had moderate or frequent diffuse plaques (n = 19, 49%). By the National Institute on Aging-Reagan Institute (NIA-RI) criteria, none of our cases met criteria for high "likelihood" of AD. Four met NIA-RI criteria for intermediate "likelihood." Seven cases met CERAD criteria for possible AD. Nineteen met Khachaturian criteria for AD. Only 1 subject had neocortical Lewy bodies. Small, old infarcts were common, but no subjects had more than 2 of these and none had a single large infarction. Thus, the majority of individuals who are cognitively normal near the time of their death have minimal amounts of tau-positive neuritic pathology (Braak stage <IV and neuritic plaques <6 per x100 field in the most affected neocortical region). The few subjects with more severe AD pathology can be expected based on incidence rates of AD in the very elderly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656067     DOI: 10.1093/jnen/62.11.1087

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  252 in total

1.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  Entorhinal verrucae geometry is coincident and correlates with Alzheimer's lesions: a combined neuropathology and high-resolution ex vivo MRI analysis.

Authors:  Jean C Augustinack; Kristen E Huber; Gheorghe M Postelnicu; Sita Kakunoori; Ruopeng Wang; André J W van der Kouwe; Lawrence L Wald; Thor D Stein; Matthew P Frosch; Bruce Fischl
Journal:  Acta Neuropathol       Date:  2011-12-13       Impact factor: 17.088

Review 4.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

5.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

6.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

7.  Cerebrovascular disease, β-amyloid, and cognition in aging.

Authors:  Natalie L Marchant; Bruce R Reed; Charles S DeCarli; Cindee M Madison; Michael W Weiner; Helena C Chui; William J Jagust
Journal:  Neurobiol Aging       Date:  2011-11-01       Impact factor: 4.673

8.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 9.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

10.  Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment.

Authors:  Jagan A Pillai; Linda K McEvoy; Donald J Hagler; Dominic Holland; Anders M Dale; David P Salmon; Douglas Galasko; Christine Fennema-Notestine
Journal:  J Clin Exp Neuropsychol       Date:  2012-08-21       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.